

Lorenzo Bertani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1750477/publications.pdf>

Version: 2024-02-01

61
papers

1,583
citations

304368

22
h-index

329751

37
g-index

61
all docs

61
docs citations

61
times ranked

2005
citing authors

#	ARTICLE	IF	CITATIONS
1	From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. <i>World Journal of Gastroenterology</i> , 2018, 24, 3681-3694.	1.4	123
2	Association Between Baseline Impedance Values and Response Proton Pump Inhibitors in Patients With Heartburn. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1082-1088.e1.	2.4	121
3	The PROSIT-BIO Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 233-243.	0.9	116
4	Effect of <i>Lactobacillus paracasei</i> CNCM 1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. <i>United European Gastroenterology Journal</i> , 2018, 6, 604-613.	1.6	77
5	Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?. <i>Neurogastroenterology and Motility</i> , 2014, 26, 28-35.	1.6	73
6	Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. <i>Environmental Microbiology</i> , 2018, 20, 3201-3213.	1.8	59
7	Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. <i>American Journal of Gastroenterology</i> , 2016, 111, 1711-1717.	0.2	55
8	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 568-579.	0.9	51
9	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1079-1088.	0.6	50
10	Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study. <i>Ecological Management and Restoration</i> , 2016, 29, 197-204.	0.2	49
11	Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 284-291.	1.9	41
12	The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 713-719.	1.4	40
13	Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482098086.	1.4	40
14	Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1579-1587.	0.9	39
15	Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00174.	1.3	35
16	A Low-FODMAP Diet for Irritable Bowel Syndrome: Some Answers to the Doubts from a Long-Term Follow-Up. <i>Nutrients</i> , 2020, 12, 2360.	1.7	34
17	Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1091-1098.	0.8	32
18	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 1189-1197.	1.6	31

#	ARTICLE	IF	CITATIONS
19	Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1296-1305.	1.1	30
20	Irritable bowel syndrome and chronic constipation: Fact and fiction. <i>World Journal of Gastroenterology</i> , 2015, 21, 11362.	1.4	28
21	Esophageal testing: What we have so far. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2016, 7, 72.	0.5	26
22	Pros and Cons of the SeHCAT Test in Bile Acid Diarrhea: A More Appropriate Use of an Old Nuclear Medicine Technique. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-9.	0.7	25
23	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the <sc>IG-IBD LIVE</sc> study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 95-109.	1.9	25
24	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.4	22
25	Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 62-69.	0.9	21
26	Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. <i>Scientific Reports</i> , 2021, 11, 10368.	1.6	21
27	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1323.	1.0	20
28	Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions?. <i>Nutrients</i> , 2021, 13, 1387.	1.7	20
29	Barrett's esophagus in 2016: From pathophysiology to treatment. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 190.	0.6	18
30	Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 273-280.	1.9	18
31	Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	0.7	17
32	Low Fermentable Oligo- Di- and Mono-Saccharides and Polyols (FODMAPs) or Gluten Free Diet: What Is Best for Irritable Bowel Syndrome?. <i>Nutrients</i> , 2020, 12, 3368.	1.7	17
33	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020, 8, 1228-1235.	1.6	16
34	Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199990.	1.4	16
35	Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure. <i>Ecological Management and Restoration</i> , 2016, 29, 3-9.	0.2	15
36	Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> in Crohn's disease: pharmacological and clinical implications. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 79-88.	1.4	14

#	ARTICLE	IF	CITATIONS
37	Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00177.	1.3	14
38	Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring. <i>Digestive and Liver Disease</i> , 2015, 47, 1027-1032.	0.4	12
39	Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease. <i>Digestive and Liver Disease</i> , 2017, 49, 978-983.	0.4	12
40	Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis. <i>Nutrients</i> , 2021, 13, 608.	1.7	12
41	Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis. <i>Inflammation</i> , 2022, 45, 1829-1847.	1.7	11
42	A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110314.	1.4	10
43	Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 65, 298-308.	2.2	10
44	Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. <i>Digestive and Liver Disease</i> , 2022, 54, 1367-1373.	0.4	10
45	Inflammatory Bowel Diseases: It's Time for the Adenosine System. <i>Frontiers in Immunology</i> , 2020, 11, 1310.	2.2	7
46	Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110233.	1.4	7
47	Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2397-2402.	1.1	6
48	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e134-e136.	0.9	6
49	Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6325.	1.8	5
50	Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1845-1852.	0.6	5
51	Ig Glycosylation in Ulcerative Colitis: It's Time for New Biomarkers. <i>Frontiers in Pharmacology</i> , 2021, 12, 654319.	1.6	4
52	Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. <i>Pharmaceuticals</i> , 2021, 14, 1230.	1.7	4
53	The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?. <i>Gastroenterology</i> , 2021, 160, 1903-1904.	0.6	3
54	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness, safety and immunogenicity in a large cohort of IBD patients. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 97-104.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	0.8	3
56	Su1903 as Early Measurement of Serum Cytokines As Predictor of Clinical and Endoscopic Outcome to Vedolizumab in Patients with Ulcerative Colitis. Gastroenterology, 2019, 156, S-654.	0.6	1
57	Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease"what about mucosal healing and biomarkers?. Alimentary Pharmacology and Therapeutics, 2020, 52, 751-752.	1.9	1
58	Reply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF. Inflammatory Bowel Diseases, 2020, 26, e104-e104.	0.9	1
59	Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak. Journal of Clinical Medicine, 2021, 10, 3270.	1.0	1
60	Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab"authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1082-1082.	1.9	0
61	Editorial: can serum triiodothyronine to thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 348-349.	1.9	0